Compare MBBC & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | RNXT |
|---|---|---|
| Founded | 1902 | 2012 |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 38.8M |
| IPO Year | N/A | 2021 |
| Metric | MBBC | RNXT |
|---|---|---|
| Price | $15.00 | $0.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 7.9K | ★ 220.3K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $9.97 | $0.70 |
| 52 Week High | $15.79 | $1.45 |
| Indicator | MBBC | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 45.13 |
| Support Level | $12.90 | $0.81 |
| Resistance Level | $15.60 | $1.07 |
| Average True Range (ATR) | 0.38 | 0.05 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 32.10 | 28.88 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.